Caveolin‑1 is a membrane-associated protein expressed in many cell types that plays a key role in modulating inflammatory ...
A trio of studies from the Association for Research in Vision and Ophthalmology (ARVO) 2026 Annual Meeting show the potential of several emerging treatments for dry eye disease.
Safety signals with faricimab in routine practice, including intraocular inflammation and endophthalmitis, aligned with prior ...
VectorBuilder, a global leader in gene delivery technologies and CDMO solutions, will participate in the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting, taking place in ...
OKYO Pharma Ltd (NASDAQ:OKYO), a clinical-stage biopharmaceutical company developing therapies for neuropathic corneal pain (NCP) and inflammatory eye diseases, announced that its abstract has been ...
PulseSight Therapeutics SAS, an ophthalmology clinical stage biotech company developing disruptive non-viral vectorized gene therapies with minimally-invasive delivery technology, has reported the ...
Key findings from the DME AWARE initiative highlight the importance of non-invasive treatment options for early intervention ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results